Fordyce Marshall, President and Chief Executive Officer of Vera Therapeutics, Inc. (NASDAQ:VERA), executed a series of stock sales totaling approximately $1.96 million on July 7, 2026. The transactions involved 46,250 shares of Class A Common Stock, with prices ranging from $40.39 to $43.97 per share. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan established on January 9, 2026. The sale prices closely mirrored the stock's current trading level of $42.45, reflecting the company's $3.03 billion market capitalization and a 75% return over the past year. According to InvestingPro analysis, the stock may be undervalued at current levels, with subscribers accessing detailed Fair Value estimates and 11 additional ProTips.
The divestment occurred across multiple transactions at varying weighted-average prices. Marshall sold 1,000 shares at a weighted-average price of $40.7762, with individual transactions ranging from $40.39 to $41.31. An additional 32,550 shares were sold at a weighted-average price of $42.0736, with prices in this block ranging from $41.40 to $42.39. Further sales included 10,500 shares at a weighted-average price of $42.8578, with prices between $42.40 and $43.38, and 2,200 shares at a weighted-average price of $43.5947, with prices ranging from $43.42 to $43.97.
Following these transactions, Marshall directly holds 151,994 shares of Vera Therapeutics Class A Common Stock. Additionally, he indirectly holds 122,949 shares through a Grantor Retained Annuity Trust (GRAT) and 99,081 shares through a Trust.
In other recent news, Vera Therapeutics has received accelerated approval from the U.S. Food and Drug Administration for its drug Trutakna (atacicept) to treat IgA nephropathy. This approval is based on interim results from the ORIGIN 3 trial, showing significant reductions in proteinuria among patients. Following this announcement, several analyst firms have adjusted their outlooks for Vera Therapeutics. Cantor Fitzgerald reiterated an Overweight rating with a $100 price target, while Guggenheim increased its price target to $76, maintaining a Buy rating. Additionally, H.C. Wainwright raised its price target to $125, also maintaining a Buy rating. The company has set a list price of $425,000 per patient per year for Trutakna. In personnel news, Nancy Boman has been named chief regulatory officer, succeeding William Turner, who will transition to a strategic advisor role. Turner played a key role in overseeing the recent drug approval process.
The biotech sector continues to navigate a complex regulatory and pricing landscape. Vera Therapeutics' recent FDA approval and subsequent analyst upgrades highlight the potential for commercial success in rare disease treatments. However, the executive's stock sale under a pre-arranged plan underscores the importance of monitoring insider activity for insights into management's confidence and valuation perceptions. The company's market capitalization and recent stock performance suggest a growing investor interest in its pipeline and commercial prospects.